Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerenis Therapeutics, a biopharmaceutical company focused on discovering and developing new HDL therapies, has completed a Phase 1 study of the company's CER-001 investigational product candidate to treat patients with acute coronary syndromes.
Subscribe to our email newsletter
Cerenis Therapeutics said that results of the completed study provide evidence that the investigational therapy was safe and well-tolerated at all dose levels evaluated, including those intended for future clinical development.
Cerenis Therapeutics stated that the Phase 1 randomised, double-blind, placebo-controlled, cross-over, single rising dose study of 32 healthy dyslipidemic human volunteers, was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous infusions of CER-001.
In the study, each subject received dosages up to 45mg/kg and placebo in a two period crossover design. No drug related adverse events were reported for CER-001, and cholesterol mobilisation was observed at dose levels of 2mg/kg and higher.
Reportedly, the results from this study were consistent with pre-clinical findings in demonstrating evidence of dose-related cholesterol mobilisation, as well as evidence of substantial increases in HDL-cholesterol levels. Because of these properties, we believe that administration of CER-001 may promote reverse cholesterol transport and stimulate cholesterol removal in patients.
Jean-Louis Dasseux, CEO of Cerenis Therapeutics, said: “These positive results represent an important milestone for the CER-001 program and Cerenis Therapeutics’ approach to developing potent HDL mimetics.
“The data are strongly supportive of continued clinical development of CER-001 as a treatment for patients with high-risk atherosclerosis, including acute coronary syndromes.”